cadonilimab + AK117 + oxaliplatin + tegafur-gimeracil-oteracil potassium

This drug is a combination regimen consisting of four agents for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and possibly other solid tumors. - **Cadonilimab** is a tetrameric bispecific monoclonal antibody targeting PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), designed to block these immune checkpoints and enhance anti-tumor immune response[1][2][5]. - **AK117 (ligufalimab)** is a next-generation humanized IgG4 monoclonal antibody targeting CD47, blocking the CD47-SIRPα pathway to prevent tumor cell evasion of phagocytosis by macrophages without hemagglutination[1][3][4]. - **Oxaliplatin** is a platinum-based cytotoxic chemotherapy agent causing DNA crosslinking and apoptosis[1]. - **Tegafur-gimeracil-oteracil potassium** (S-1) is an oral combination chemotherapy: tegafur is a prodrug of fluorouracil; gimeracil inhibits dihydropyrimidine dehydrogenase to increase fluorouracil levels; oteracil potassium reduces gastrointestinal toxicity[1]. The combination is administered as an investigative first-line therapy for advanced, HER2-negative gastric or gastroesophageal junction adenocarcinoma, and under study for other cancers such as hepatocellular carcinoma[1][2][4]. The mechanism involves blockade of immune checkpoints to restore anti-tumor immunity (cadonilimab, AK117) plus cytotoxic chemotherapy (oxaliplatin, S-1).

Other names

ligufalimab + cadonilimab + oxaliplatin + tegafur-gimeracil-oteracil potassium